RedHill Biopharma develops medicines for gastrointestinal and infectious diseases, promoting drugs like Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage programs include RHB-204, opaganib, RHB-107, RHB-104, and RHB-102.
RDHL has been in the news recently: REDHILL BIOPHARMA is not directly mentioned in the provided information. However, the biopharma industry is highlighted through Theravance Biopharma's upcoming presentation, Solstice Health's AI platform for marketing content review, Hansa Biopharma's product sales growth, and Be Biopharma's study on plasma cell engraftment in non-human primates.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
